Gu ZC, et al. - In a systematic review and meta-analysis of data from randomized controlled trials and real-world studies, researchers ascertained if the use of non-vitamin K antagonist oral anticoagulants (NOACs) correlates with increased risk of major gastrointestinal bleeding (GIB) vs conventional therapies (such as vitamin K antagonists or anti-platelet agents). Data from 43 randomized controlled trials (183,752 patients) and 41 real-world studies (1,879,428 patients) were analyzed. The authors concluded that no significant difference was found in the risk of major GIB between patients receiving NOACs compared to conventional treatment. Users of Rivaroxaban had increased the risk of major GIB by 39%.